As Evidence Grows for Role of microRNAs in Disease, Drugmakers Focus on Select Targets

Despite the mounting data linking a variety of miRNAs to different diseases, in most cases the data are early-stage, and thus far only a handful of miRNAs have made it into the pipelines of companies in the field.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories